The 2026 Part D Out-of-Pocket Cap and the Medicare Prescription Payment Plan

The 2026 Part D Out-of-Pocket Cap and the Medicare Prescription Payment Plan: What It Means for Orlando-Area Medicare Shoppers

Quick Answer: The 2026 Medicare Part D out-of-pocket cap is $2,100 per year, and once a beneficiary hits that number they owe $0 for covered drugs for the rest of the plan year. The Medicare Prescription Payment Plan (M3P) lets anyone spread that $2,100 across monthly installments instead of paying it in a lump sum early in the year. For Medicare beneficiaries in Orange County and across the Orlando metro, this cap applies the same way whether they're enrolled in one of the dozens of Medicare Advantage plans available locally or a standalone Part D plan paired with Medigap.

This is a federal rule. It works the same whether a beneficiary lives in a small town or a major metro, and it applies on every Part D plan nationwide, whether that drug coverage is standalone or bundled into a Medicare Advantage plan. Orange County alone has well over 40 Medicare Advantage plan options each year, many built around the AdventHealth and Orlando Health hospital networks that dominate Central Florida care, and local SHINE (Serving Health Insurance Needs of Elders) counselors through the Department of Elder Affairs field questions on exactly this kind of plan-year change during Annual Enrollment Period. This article does not repeat the Plan G versus Plan N premium comparisons already covered elsewhere on IM65 — it focuses specifically on what the Part D cap and M3P mean for anyone choosing between Medicare Supplement and Medicare Advantage coverage in 2026, with particular attention to what that decision looks like for Orlando-area shoppers.

What Is the 2026 Medicare Part D Out-of-Pocket Cap?

The 2026 Part D out-of-pocket cap is $2,100, up from $2,000 in 2025. Once a beneficiary's true out-of-pocket drug spending reaches that amount in a calendar year, covered prescriptions cost $0 for the remainder of the year under every Medicare path, whether a standalone Part D plan or the drug coverage built into a Medicare Advantage plan.

This cap exists because of the Inflation Reduction Act, and 2026 is the second year it's in effect after replacing the old system of deductible, initial coverage, coverage gap (the "donut hole"), and catastrophic coverage phases. That old catastrophic phase is gone entirely. In its place is a single number: $2,100. CMS confirmed this figure through official guidance, available at CMS.gov.

The maximum Part D deductible for 2026 is $615, and the plan a beneficiary picks determines how quickly they move through the deductible and initial coverage stages toward that $2,100 ceiling. A plan's specific deductible, formulary tier structure, and pharmacy network still matter, which is why comparing current plan documents every fall during the Annual Enrollment Period remains worthwhile even with a flat national cap in place — and why many Orange County beneficiaries sit down with a local SHINE counselor or an IM65 Approved Advisor serving Orlando-area ZIP codes each fall to re-check formularies against the pharmacies they actually use.

Why the Catastrophic Phase Disappearing Matters

Before 2025, beneficiaries with expensive specialty drugs — cancer treatments, multiple sclerosis therapies, certain rheumatoid arthritis medications — could pay 5% coinsurance indefinitely once they reached catastrophic coverage, with no true ceiling. A person on a $12,000-a-year specialty drug could easily pay several thousand dollars out of pocket annually. Under the 2026 rule, that same person pays no more than $2,100 total for covered drugs, full stop.

How Does the Medicare Prescription Payment Plan (M3P) Work?

The Medicare Prescription Payment Plan lets any Part D enrollee — on a standalone drug plan or a Medicare Advantage plan with drug coverage — split their $2,100 in annual out-of-pocket drug costs into level monthly payments spread across the rest of the plan year, instead of paying large amounts upfront at the pharmacy counter.

M3P does not reduce what a beneficiary owes. The $2,100 cap is the cap whether someone uses M3P or not. What M3P changes is the timing. Without it, someone who fills a single expensive prescription in January could hit their full $2,100 obligation at the pharmacy counter in one visit. With M3P, that same person's plan bills them in installments — the earlier in the year they opt in, the smaller each monthly payment, since the remaining cost is divided across more months.

A beneficiary opts in through their Part D plan, not through Medicare directly, and every Part D sponsor nationwide is required to offer it. There's no extra premium for choosing M3P — it reorganizes payment timing, not the total bill.

Who Benefits Most From M3P?

M3P is most useful for people who:

• Fill one or two high-cost specialty prescriptions early in the year and would otherwise face a large bill in January or February
• Live on a fixed monthly income and prefer predictable payments over lump sums
• Have drug costs concentrated in certain months rather than spread evenly

It's less useful for someone whose drug costs are low and spread evenly across the year, since there's nothing large to smooth out. Beneficiaries who already struggle to afford even a spread-out monthly payment should ask whether they qualify for Extra Help, the federal low-income subsidy program, which has income and asset limits well above what many people assume.

Does the Part D Cap Change the Medigap vs. Medicare Advantage Decision in Orange County?

Yes. Before the $2,100 cap took effect, Medicare Advantage's built-in drug coverage and lower premiums made it the default pick for many people worried about prescription costs. Now that every Medicare path shares the same $2,100 ceiling on drug spending, the decision between Medigap and Medicare Advantage depends more on medical cost protection and provider access than on drug costs alone — a question that carries extra weight in a market like Orlando, where Medicare Advantage HMOs frequently anchor their networks around a single hospital system.

Medigap plans don't cover prescriptions at all — a Medigap policyholder pairs it with a standalone Part D plan. But because the $2,100 cap applies equally to standalone Part D plans, a Medigap-plus-Part D combination no longer carries a drug-cost disadvantage compared to Medicare Advantage the way it arguably did in past years. That shifts the real comparison toward what each path does for hospital stays, specialist access, and out-of-network care. For a beneficiary whose cardiologist is at AdventHealth but whose oncologist practices through Orlando Health, a Medicare Advantage HMO network built around just one system can force a hard choice that a Medigap policy, usable anywhere Medicare is accepted, simply avoids — a question already explored in detail in Medicare Supplement vs. Medicare Advantage in Orlando 2026.

Medicare Advantage vs. Medicare Supplement: 2026 Feature Comparison

Medicare Advantage plan networks matter in this comparison, and nowhere more locally than in Orange County, where a Medicare Advantage HMO can restrict a member to a specific hospital system — AdventHealth or Orlando Health, in most cases — while a Medigap policyholder can see any provider nationwide who accepts Medicare. Anyone considering a switch should check the plan's 2026 provider directory directly before enrolling, since networks can and do change year to year.

2026 Part D Cap and M3P: What the Numbers Look Like in Practice

Here's a simplified look at how the cap and M3P interact for a beneficiary with high drug costs early in the year:

The total never changes — $2,100 is $2,100 either way. M3P is a cash-flow tool, not a discount.

Beneficiaries who are moving from Medicare Advantage back to Original Medicare and a Medigap policy within their first year should also understand the federal trial right that lets them do so without medical underwriting in many circumstances, detailed in Medicare Trial Rights in 2026. And anyone whose income pushes them into an IRMAA bracket should check how that separately affects their Part B premium — $202.90 per month in 2026 for most beneficiaries before any IRMAA surcharge — and Part D surcharge, covered in The IRMAA Two-Year Lookback.

How Does the Drug Price Negotiation Program Affect the 2026 Cap?

Starting January 1, 2026, the first ten drugs negotiated under the Inflation Reduction Act — including Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and Fiasp/NovoLog — carry a federally negotiated Maximum Fair Price. No other drug carries a negotiated price in 2026; a second group of 15 drugs doesn't take effect until January 1, 2027.

For beneficiaries taking one of these ten drugs, the negotiated price lowers what they pay at the pharmacy counter, which can mean reaching the $2,100 cap more slowly — and in some cases, staying under it for the whole year. CMS estimates this will save beneficiaries roughly $1.5 billion in out-of-pocket costs annually. Details on the negotiation program and the specific drug list are available through CMS.gov.

Why the Cap Strengthens the Case for Pairing Medigap With a Strong Part D Plan

Before the $2,100 cap, someone choosing Medigap had to weigh an added, sometimes significant, open-ended drug cost risk against Medicare Advantage's bundled coverage. With a hard annual ceiling now applied identically across every Part D plan — standalone or bundled — that risk gap has mostly closed. The remaining differences come down to premium cost, provider network flexibility, and whether someone wants nationwide access without referrals.

For someone who travels seasonally, sees specialists outside a narrow network, or simply wants the freedom to use any provider accepting Medicare, a Medigap-plus-Part D pairing now carries less drug-cost downside than it did even two years ago. For someone whose providers are all inside a Medicare Advantage network and who values the $0-premium and extra benefit options many plans still offer in Orange County, Medicare Advantage remains a reasonable fit. Neither path is universally better — the right one depends on individual health needs, finances, and provider relationships, and should be reviewed every year during Annual Enrollment Period, since plan details, formularies, and even carrier participation change annually.

Frequently Asked Questions

Does the $2,100 cap apply to every drug, including brand-name specialty medications?

The cap applies to total out-of-pocket spending on drugs covered by a Part D formulary, including brand-name and specialty tiers, as long as the drug is on the plan's covered list. Drugs not on a plan's formulary don't count toward the cap, which is why checking a plan's formulary before enrolling matters.

Is there a fee or interest charge for using the Medicare Prescription Payment Plan?

No. M3P reorganizes the timing of payments already owed under the $2,100 cap; it does not add interest, fees, or any additional cost. A beneficiary pays the same total amount whether they use M3P or pay at the pharmacy as costs occur.

Can I switch from the Medicare Prescription Payment Plan back to paying at the pharmacy mid-year?

Yes, a beneficiary can opt out of M3P during the plan year, though specific timing rules apply and vary by plan administration. Anyone considering this should contact their Part D plan directly or speak with an IM65 Approved Advisor about how a mid-year change affects their remaining monthly installments.

Sources

• Centers for Medicare & Medicaid Services, "Medicare Costs" — https://www.medicare.gov/basics/costs/medicare-costs (accessed October 2026)
• Centers for Medicare & Medicaid Services, CMS Newsroom — https://www.cms.gov/newsroom (accessed October 2026)
• Federal Register, "Request for Information; Medicare Part D Reasonable and Relevant Pharmacy Contracting Standards" — https://www.federalregister.gov/documents/2026/09/24/2026-19535/request-for-information-medicare-part-d-reasonable-and-relevant-pharmacy-contracting-standards (accessed October 2026)
• CMS Data, Medicare Monthly Enrollment Dataset — https://data.cms.gov (accessed October 2026)

We do not offer every plan available in your area. Please contact Medicare.gov or 1-800-MEDICARE (1-800-633-4227), 24 hours a day/7 days a week, to get information on all of your options. TTY users should call 1-877-486-2048.